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Stephan Beck1* and Tony Ng2,3,4*Despite fantastic progress in research over the past dec-
ade, cancer remains a major source of mortality world-
wide. In the UK, for instance, cancer overtook
circulatory diseases as the leading cause of death in 2011
[1]. Early detection would obviously be best to reduce
this burden, but it requires exquisitely sensitive technol-
ogy and population-wide screening programs. Short of
finding a cure for cancer, turning cancer into a clinically
manageable chronic disease like diabetes would be a
major step forward. In this Editorial, we introduce a
Genome Medicine series on cancer epigenomics [http://
genomemedicine.com/series/cancerepigenomics], and dis-
cuss progress towards turning cancer into chronic
disease with a focus on epigenomics.
For cancers for which appropriate treatment options
are available, the proposed cancer to chronic disease
(C2c) approach (Figure 1) requires two key components:
first, knowledge of the precise localization and quantifi-
cation of the cancer burden anywhere in the body, which
can be achieved by non-invasive whole-body imaging
[2,3]; and second, knowledge of the precise molecular
signature of the evolving cancer burden to reiteratively
tailor treatments predicted to be most effective in com-
bating the establishment of resistance and subsequent
relapse. This can be achieved by (epi)genomic profiling
of cancer-specific components isolated from minimally
invasive blood samples, also known as liquid biopsies
[4]. After all, ‘Blut ist ein ganz besonderer Saft,’ as already
noted by Faust - the scholar who was striving to know
everything - in Johann Wolfgang von Goethe’s 1808 play
Faust Part I [5].The (epi)genomic landscape of cancer
Cancer is essentially a disease of the genome and the
epigenome. To understand the (epi)genomic landscape
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unless otherwise stated.both mutations and epimutations, which is exactly what
the Cancer Genome Atlas [http://cancergenome.nih.gov/],
the International Cancer Genome Consortium [www.
icgc.org] and related efforts such as BLUEPRINT [http://
www.blueprint-epigenome.eu/] are in the process of
doing for all major types of cancer. The first pan-cancer
analyses of the data generated so far have already re-
vealed valuable insights into commonalities, differences
and emergent themes across tumor lineages with regard
to mutations [6,7] and somatic copy number alterations
[8]. Similar analyses are now required for epimutations
as well as combined and combinatorial effects of gen-
omic and epigenomic alterations. The recent discovery
of numerous and highly recurrent mutations in epige-
nome modifiers such as specific DNA methyltransferases
(for example, DNMT1) and histones (for example, H3.3)
have highlighted the importance of epigenetic mecha-
nisms in cancer [9]. Indeed, in many cancers, epimuta-
tions occur more frequently than mutations [10]. The
challenge for approaches such as C2c is to extract the
key information for each cancer from the vastness of
available data. This can be achieved by computational
modeling to reduce complex multi-dimensional data
into less complex biomarkers that are more suitable for
downstream patient monitoring. A pioneering example of
this is OncoTrack [http://www.oncotrack.eu/], Europe’s
largest public-private biomarker consortium, in which this
approach is applied to colorectal cancer.Liquid biopsy and imaging - the bow and arrow
of C2c
The appeal of using liquid versus tumor biopsies for pa-
tient monitoring is obvious and well documented [3].
First, liquid biopsies allow longitudinal sampling using a
routine and minimally invasive procedure (blood sam-
pling). Second, they have the potential to capture the
majority of the cancer burden and not just the primary
tumor or metastases that are accessible through solid bi-
opsies. Third, liquid biopsies are information-rich.
As illustrated in Figure 1, key components of the
evolving cancer burden can be analyzed from a single li-
quid biopsy, such as circulating tumor cells shed fromLtd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Illustration of the cancer to chronic disease (C2c) approach. (a) C2c core technologies: liquid biopsies (LB) and whole-body imaging
(IM). For LB, current assays include circulating tumor cells and circulating tumor DNA as well as microRNAs. Examples of other biomarkers are
prostate-specific antigen as exemplar protein biomarker, and 2-hydroxyglutarate as exemplar epigenetic oncometabolite, which is a potent inhibi-
tor of TET demethylases. For IM, current platforms include, for example, magnetic resonance imaging, positron emission tomography and sodium
iodide symporter imaging. Images: circulatory system image obtained from Wikimedia Commons (LadyofHats); magnetic resonance image of
prostate cancer metastases obtained from Wikimedia Commons (Radswiki); whole body scanner image obtained with permission from Hitachi
Medical Systems. (b) Example of longitudinally measured LB and IM signals in response to treatment. The color code in the LB track represents
the evolving omic heterogeneity of the cancer, which in turn informs the next best treatment(s). The dotted line denotes the threshold between
cancer and chronic disease. The aim is to keep both the LB and IM signals within the range defined as chronic disease.
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DNA isolated from blood plasma or serum, and cancer-
specific microRNAs that are enriched in exosomes(50 to 200 nm vesicles), as well as proteins and onco-
metabolites. Recent progress in digital PCR and targeted
next-generation sequencing has revealed that circulating
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tients [11] and is informative for monitoring acquired
resistance to cancer therapy [12].
In addition to localizing tumors as well as metastases,
whole-body molecular imaging can also be used to non-
invasively probe tumor heterogeneity, which describes the
existence of subpopulations of cancer cells with distinct
(epi) genotypic, proteomic and phenotypic variations. Spe-
cifically, it can provide important spatiotemporal informa-
tion concerning tumor progression to aid treatment
decisions for individual cancer patients. As examples,
ErbB2/HER2 and sodium iodide symporter (NIS) imaging
can be employed to discern the difference or discordance
in protein expression (HER2 status, which is used in the
clinic to assign therapies such as trastuzumab [13]) and the
differential sensitivity to chemotherapy [14], respectively,
between primary tumor and the corresponding metastases.
For instance, patients who had a HER2-negative primary
tumor may have HER2-positive metastases that may not
be amenable to biopsy, so treatment such as trastuzumab
may be incorrectly withheld if the clinical decision is based
on the HER2 status of the archived primary tumor sample
alone. Similarly, using preclinical NIS imaging, response to
chemotherapy has been shown to be heterogeneous among
the primary tumor and metastases in different organ/tissue
microenvironments within the same animal. Molecular im-
aging may also provide a non-invasive means of monitor-
ing and quantifying the emergence of potential treatment
resistance mechanisms such as ERBB2 [15] and MET [16]
amplifications as well as KRAS mutations [17], which have
been known to arise in response to selection pressure of
targeted therapies [18]; the latter (treatment targeting
EGFR, for example) have, to date, only achieved modest
improvements in clinical outcome [19,20].
A key advantage of integrating liquid biopsy-based omics
and imaging is to harness the combined sensitivities and
specificities of molecular imaging and next-generation se-
quencing techniques in order to facilitate early detection of
the treatment-resistant variants that evolve as a mechanism
of acquired resistance. As the sensitivity of next-generation
sequencing improves towards single cell resolution, molecu-
lar imaging would still provide complementary information
that reports on the spatial heterogeneity of treatment re-
sponse, such as between different metastatic sites [14], as
well as elucidating the functional significance of the genomic
changes observed in the plasma (for example, metabolic im-
aging in the context of IDH1 and IDH2 mutations [21]). For
C2c, the combined use of imaging and liquid biopsies will
provide the most comprehensive monitoring of the cancer
burden that can be achieved by non-invasive technology.
Bottlenecks
Despite many advances and the announcement of the
US$1,000 genome earlier this year, technology remains amajor challenge for analyzing liquid biopsies. In particu-
lar, epigenomic analyses need to catch up with what is
already possible at the genomic level as mentioned
above. For C2c to succeed in turning cancer into chronic
disease, we would need to clinically adopt an effective
surveillance strategy, namely, non- or minimally invasive
monitoring of patients for treatment-resistant tumor
variants that evolve as a mechanism of acquired resist-
ance, as diabetes is chronically managed by monitoring
blood glucose levels. An example of this would be
chronic myelogenous leukemia (CML), a disease in
which most patients still harbor residual disease despite
an early identification of a specific chromosomal abnor-
mality that can be targeted with a tyrosine kinase inhibi-
tor (imatinib) [22]. An active surveillance program
(combining molecular imaging - for example, Abl kinase
positron emission tomography (PET) imaging using a
radiolabeled small molecule inhibitor [23] - and liquid
biopsies) could be used to track the molecular evolution
of the Abl kinase that is subjected to treatment pressure,
and where necessary, new second- and third-generation
tyrosine kinase inhibitors can be introduced. Although
several targeted therapies are available (for example,
against EGFR, HER2/neu, HER3, BCR-ABL, PI3 kinase,
Akt, MEK, BRAF, CD20, TOR and VEGF), more are
needed, particularly for some cancers, such as pancreatic
carcinoma, which is still associated with a dismal out-
come and for which there are limited therapeutic op-
tions. Epigenetics may help to overcome this limitation
by sensitizing cancers to existing treatments to which
the cancer was not previously responsive. For example,
recent pioneering studies have shown that treatment of
cancer cell lines and patients with drugs targeting epi-
genetic alterations, such as DNA methylation, showed
upregulation of immune-modulatory pathways, thus sen-
sitizing these cancers for possible treatment with exist-
ing immune therapies [24,25].
Outlook
There is currently unprecedented consensus among
researchers, clinicians, politicians and the wider public
that omics in one form or another will transform future
healthcare, including the treatment and management
of cancer. By combining omics with imaging, the C2c
strategy introduced here will be one step towards this
transformation. Once fully developed and established,
it may also be applicable to early detection using
population-wide screening and thus become an integral
part of personalized medicine. Although much remains
to be done, the progress made so far suggests that for
C2c to succeed will not require ‘a pact with the devil’,
unlike the case of poor Dr Faust who had to give
his soul to Mephistopheles to succeed in his quest for
ultimate knowledge.
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